相关实验视频
Updated: Sep 20, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
在GRADE中随机降血糖治疗的住院病人的关联
Daniel S Hsia1,2, Naji Younes3, Alokananda Ghosh3
1Pennington Biomedical Research Center, Baton Rouge, LA.
Diabetes care
|May 27, 2025
概括
在糖尿病血糖降低方法 (GRADE) 研究中,住院病例很常见. 与glimepiride相比,liraglutide显示后续住院的风险较低,可能会影响治疗选择.
科学领域:
- 内分泌学 在内分泌学.
- 糖尿病管理 糖尿病管理
- 临床试验 临床试验
背景情况:
- 住院是管理2型糖尿病的一个重要问题.
- 糖尿病血糖降低方法 (GRADE) 研究比较了多种降血糖药物.
- 了解住院风险因素对于患者护理至关重要.
研究的目的:
- 为了比较住院率,并确定GRADE研究参与者的风险因素.
- 评估服用甲福明并随机分配给胰岛素格拉金,格莱梅皮里德,利拉格卢提德或西塔格利普丁的患者的住院病例.
主要方法:
- 使用了治疗意图 (N=5,047) 和分配治疗 (N=4,830) 数据集.
- 雇员Kaplan-Meier分析用于首次住院的时间和对随后住院风险的时间-事件分析.
- 评估住院和非住院参与者之间的基线差异.
主要成果:
- 超过三分之一的参与者 (32.4%) 至少有一次住院治疗.
- 在ITT分析中,在治疗组之间没有发现首次住院病例发生率的显著差异.
- 在AT分析 (HR 0.78) 中,利拉古类药物显示了首次住院的危险率降低,而格利梅皮里德则降低了.
- 增加后入院风险的因素包括血糖控制不佳 (HbA1c>7.5%),先前入院和治疗变化.
- 与glimepiride相比,利拉格卢提德的分配将随后住院的风险降低了13%.
结论:
- 在GRADE研究中,住院病例很常见,在初始治疗组中发生的病例率相似.
- 与glimepiride相比,使用liraglutide观察到随后住院风险的适度但统计学上显著降低.
- 这些发现可以为类似患者群体的治疗决策提供信息.
相关概念视频
Hypoglycemia and Glucagon
353
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
353
Diabetes: Management and Pharmacotherapy
412
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
412
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K

